Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT-90: Psilocybin-Assisted Psychotherapy for Depression in PTSD
NCT06141876Phase 2Not yet recruiting
- Sponsor
- Apex Labs
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of APEX-002 in major depressive disorder (MDD), sponsored by Apex Labs. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
APEX-002
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06141876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141876.